2018
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.
Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 693-702. PMID: 29891520, DOI: 10.6004/jnccn.2018.0056.Peer-Reviewed Original ResearchConceptsPrimary neuroendocrine tumorNeuroendocrine tumorsAdrenal tumorsManagement of NETsLocoregional advanced diseaseNCCN Guidelines InsightsAdrenal gland tumorsAdvanced diseaseNCCN guidelinesAdult patientsDistant metastasisGastrointestinal tractGland tumorsTumorsNeuroendocrineManagement optionsGuidelinesPatientsPheochromocytomaMetastasisParagangliomaDiseaseTract
2017
The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors
Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O’Dorisio T, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas 2017, 46: 707-714. PMID: 28609356, PMCID: PMC5642985, DOI: 10.1097/mpa.0000000000000850.Peer-Reviewed Original ResearchConceptsMidgut neuroendocrine tumorsNeuroendocrine tumorsNorth American Neuroendocrine Tumor Society Consensus GuidelinesNorth American Neuroendocrine Tumor SocietyNETTER-1 trialRADIANT-4 studyRefractory carcinoid syndromePhase 3 studyNonfunctioning neuroendocrine tumorEnteropancreatic neuroendocrine tumorsConsensus-based guidelinesCLARINET trialRADIANT-2Carcinoid syndromeTelotristat ethylMedical managementTherapeutic optionsConsensus guidelinesSurgical guidelinesLu-DOTATATEMultidisciplinary panelProximal colonGastrointestinal tractSmall intestinePatients
2015
Role of somatostatin analogues in the treatment of neuroendocrine tumors.
Narayanan S, Kunz PL. Role of somatostatin analogues in the treatment of neuroendocrine tumors. Journal Of The National Comprehensive Cancer Network 2015, 13: 109-17; quiz 117. PMID: 25583773, DOI: 10.6004/jnccn.2015.0012.Peer-Reviewed Original ResearchConceptsNeuroendocrine tumorsSomatostatin analoguesTumor controlTreatment of NETsSystemic tumor controlHormone-related symptomsManagement of patientsRare epithelial neoplasmAdvanced diseaseHormone excessSymptom managementNeuroendocrine differentiationEpithelial neoplasmsGastrointestinal tractPatientsTumorsTreatmentDiarrheaNeoplasmsLungSerotoninSyndromeSymptomsManagementMainstay
2014
Sa1141 Clinical and Immunohistochemical Features of High Grade Neuroendocrine Neoplasia of the Gastrointestinal Tract
DiMaio M, Zemek A, Kwok S, Kunz P, Longacre T. Sa1141 Clinical and Immunohistochemical Features of High Grade Neuroendocrine Neoplasia of the Gastrointestinal Tract. Gastroenterology 2014, 146: s-210-s-211. DOI: 10.1016/s0016-5085(14)60745-9.Peer-Reviewed Original Research
2013
Diagnostic discrepancies between second-opinion and referring pathology reports of neuroendocrine tumors.
Lin H, Longacre T, Khandelwal V, Balise R, Kunz P. Diagnostic discrepancies between second-opinion and referring pathology reports of neuroendocrine tumors. Journal Of Clinical Oncology 2013, 31: 154-154. DOI: 10.1200/jco.2013.31.4_suppl.154.Peer-Reviewed Original ResearchNeuroendocrine tumorsPathology reportsMitotic indexDiagnosis of NETsHistologic classification schemeStanford University HospitalNET casesMajority of casesRare malignancyUniversity HospitalGastrointestinal tractNET diagnosisPathology guidelinesPrimary siteHistologic descriptionDiagnostic discrepanciesSmall intestineClinical diagnosisMajor discrepanciesNeuroendocrine cellsKi67DiagnosisMost reportsPathology expertsTumors